Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816).

Peter C. Black,Catherine M. Tangen,Parminder Singh,David J. McConkey,Scott Lucia,William T. Lowrance,Vadim S. Koshkin,Kelly Stratton,Trinity J. Bivalacqua,Elad Sharon,Wassim Kassouf,Sima P. Porten,Richard Carlton Bangs,Melissa Plets,Seth P. Lerner,Ian M. Thompson

Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816).

2020

Peter C. Black
Catherine M. Tangen
Parminder Singh
David J. McConkey
Scott Lucia
William T. Lowrance
Vadim S. Koshkin
Kelly Stratton
Trinity J. Bivalacqua
Elad Sharon
Wassim Kassouf
Sima P. Porten
Richard Carlton Bangs
Melissa Plets
Seth P. Lerner
Ian M. Thompson

5022Background: Radical cystectomy (RC) is the standard of care for patients with BCG-unresponsive high risk non-muscle invasive bladder cancer (NMIBC), but many patients are unfit for surgery or e...

Keywords:

non muscle invasive
Atezolizumab
Oncology
Internal medicine
Bladder cancer
Pathology
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations